A Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian Province.

A Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian Province.

Publication date: Jun 30, 2024

Immortal time bias (ITB) is common in cohort studies and distorts the association estimates between the treated and untreated. We used data from an Italian study on COVID-19 vaccine effectiveness, with a large cohort, long follow-up, and adjustment for confounding factors, affected by ITB, with the aim to verify the real impact of the vaccination campaign by comparing the risk of all-cause death between the vaccinated population and the unvaccinated population. We aligned all subjects on a single index date and considered the “all-cause deaths” outcome to compare the survival distributions of the unvaccinated group versus various vaccination statuses. The all-cause-death hazard ratios in univariate analysis for vaccinated people with 1, 2, and 3/4 doses versus unvaccinated people were 0. 88, 1. 23, and 1. 21, respectively. The multivariate values were 2. 40, 1. 98, and 0. 99. Possible explanations of this trend of the hazard ratios as vaccinations increase could be a harvesting effect; a calendar-time bias, accounting for seasonality and pandemic waves; a case-counting window bias; a healthy-vaccinee bias; or some combination of these factors. With 2 and even with 3/4 doses, the calculated Restricted Mean Survival Time and Restricted Mean Time Lost have shown a small but significant downside for the vaccinated populations.

Open Access PDF

Concepts Keywords
Accounting healthy-vaccinee bias
Death immortal time bias
Italian pandemic vaccine effectiveness
Vaccination total mortality

Semantics

Type Source Name
disease MESH COVID-19
disease VO vaccination
disease VO time
disease VO vaccine effectiveness
disease MESH death
disease VO vaccinated
disease VO population
disease VO unvaccinated
disease VO vaccinee
drug DRUGBANK Coenzyme M
disease VO effectiveness
drug DRUGBANK Trestolone
drug DRUGBANK Polyethylene glycol
disease MESH fatal outcomes
disease MESH morbidities
disease MESH comorbidity
disease VO vaccine
drug DRUGBANK Aspartame
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH hypertension
disease MESH COPD
disease MESH kidney diseases
disease MESH cancer
disease MESH infection
disease VO dose
disease VO vaccine dose
disease IDO infected population

Original Article

(Visited 1 times, 1 visits today)